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Background: Chemotherapy is the mainstay of non-Hodgkin lymphoma (NHL) treatment. Based on expert opinion,
the use of radiotherapy (RT) is currently preferred in some institutions as consolidative treatment for patients with
localized disease. The lack of conclusive data coming from conflicting studies about the impact of treatment
demands a systematic review, which could provide the most reliable assessment for clinical decision-making. We
evaluate the addition of RT post-CT, for aggressive and localized NHL (ALNHL).
Methods: Randomized controlled trials (RCT) that evaluated chemotherapy alone versus chemotherapy plus RT
were searched in databases. The outcomes were overall survival (OS), progression-free survival (PFS), overall
response rate (ORR) and toxicity. Risk ratio (RR) and hazard ratio (HR) with their respective 95% confidence intervals
(CI) were calculated using a fized-effect model.
Results: Four trials (1,796 patients) met the inclusion criteria. All trials tested the use of RT after systemic therapy
comprising anthracycline-based chemotherapy. This systematic review showed that RT enhances PFS after
chemotherapy (hazard ratio [HR] 0.81; 95% CI 0.67-0.98; p = 0.03), with no impact on ORR and OS. Some
heterogeneity between trials could limit the conclusions about OS. Toxicity data could not be pooled due to
differences in reporting adverse events.
Conclusions: This systematic review with meta-analysis shows no improvement in survival when adding RT to
systemic therapy for ALNHL. Our conclusions are limited by the available data. Further evaluations of new RT
technologies and its association with biologic agents are needed.
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Non-Hodgkin lymphoma (NHL) is the sixth most com-
mon cause of cancer death in the world [1]. About
300,000 new cases of NHL occur every year, accounting
for nearly 3% of all new cases of cancer. Among them,
more than half will die due to NHL [2].* Correspondence: sasse@cevon.com.br
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distribution, and reproduction in any mediumThere are several classifications currently in use for
NHL that are somewhat overlapping. The Revised Euro-
pean American Lymphoma (REAL) classification [3] was
initially proposed. However, a REAL-based classification
is now widely accepted, also known as the World Health
Organization (WHO) classification for hematologic
malignancies. This classification is based on cell of origin,
maturity, morphology, immunophenotype, genetic and
clinical features [4]. Considered outdated by many, the
International Working Formulation [5] (WF) had divided
NHL in low, intermediate and high grade, based on
morphology and natural history. It remains importanttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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based on this classification.
In some series, more than one third of patients with
NHL have an aggressive phenotype. For patients with
localized disease, radiotherapy (RT) was the first curative
approach and continues to be a part of combined mo-
dality therapy [6-8]. Previous studies have shown that al-
most 70% of patients with localized NHL can be cured
by RT alone [9,10]. However, the high relapse rate outside
the radiation field justifies the requirement of chemother-
apy in this setting [11,12].
Since the early 1980s, the synergistic effect of both
modalities has been evaluated, and their combination
widely advocated in the treatment of patients with NHL
[13-17]. The benefit of this strategy was first shown in a
randomized trial including 316 patients, comparing RT
versus chemotherapy versus combined therapy [18]. In
this trial, the combination arm had better failure-free
survival and OS when compared to chemotherapy alone,
or RT alone arms. The use of RT after systemic therapy
is frequently recommended, based on expert opinion, to
improve local control of the disease, and possibly to di-
minish relapse and death [19].
The lack of conclusive data coming from conflicting
studies about the impact of treatment demands a sys-
tematic review, which could provide the most reliable
assessment for clinical decision-making. The aim of this
systematic review is to assess whether adding RT to
standard chemotherapy for aggressive and localized
NHL (ALNHL) has an impact on local tumor control
and survival.
Methods
This study was approved by the Ethics Committee at
Universidade Estadual de Campinas.
Types of studies
Randomized controlled trials (RCT) were included com-
paring chemotherapy and consolidative RT versus chemo-
therapy alone for patients with ALNHL.
Types of participants
Participants included adults with ALNHL, without previ-
ous treatment. We defined localized disease as Ann
Arbor stage I and stage II with contiguous disease
encompassed by a radiation field [20]. We defined ag-
gressive NHL according to the WF [5], the REAL classi-
fication [3], or the WHO classification [4]. In older
trials, an intermediate or a high-grade classification was
permitted.
Types of outcome measures
The primary outcome was OS. Secondary outcomes of
interest were PFS, response to therapy and safety. PFSencompassed the term disease-free survival (DFS), used
when there was no residual disease.
Search strategies for identification of studies
We performed an electronic database search [21] in
MEDLINE, EMBASE, Cochrane Central Register of
Controlled Trials – CENTRAL and LILACS (until January
2010); electronic or hand searching of the conference pro-
ceedings between 1980 and 2009 of the American Society
of Clinical Oncology (ASCO), the American Society for
Therapeutic Radiology and Oncology (ASTRO), the
American Society of Hematology (ASH), the European
Conference on Clinical Oncology (ECCO) and the Euro-
pean Society of Medical Oncology (ESMO). Reference list
of all recovered trials and relevant reviews were also con-
sidered. For electronic databases, we used a sensitive
search strategy with words linked to NHL and RT.
Trial selection
Titles and abstracts of studies identified from search
strategy were screened independently by two reviewers
(LVS and JPL), according to the eligibility criteria
described above. Disagreements in the trial selection
were resolved by discussion and a third reviewer was
invited to give his opinion (ADS) if consensus was not
reached. Full-text versions of all eligible studies were
obtained for quality assessment and data extraction.
Quality assessment
The quality of each individual study was assessed inde-
pendently by two reviewers (LVS and ADS) using the
published manuscript. A specific data extraction form
was designed for assessment of quality features of studies,
such as randomization, allocation concealment, intention-
to-treat principle, similarity of treatment arms according
to known prognostic factors, follow up and drop-outs
[22,23]. Disagreements were discussed among the group
until consensus was reached.
Data extraction
A data extraction form was designed previously, and
included the following items: general identification infor-
mation (authors, title, journal, date of publication, proto-
col name, and duplication of publication), trial, type of
patients, intervention characteristics, and reported out-
comes. Data extraction was performed independently by
two reviewers (LVS and JPL) and disagreements were
resolved by consensus. When it was not possible to ob-
tain data from the published trial, we tried to contact
the authors to provide the information or additional
data.
Data were directly extracted from the published data,
or estimated from survival curves using the methods





7015 excluded articles 
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Figure 1 Flow diagram through the different phases of the
review.
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ney and colleagues [25].
Statistical analysis and synthesis
Details regarding the main methodological dimensions
empirically linked to bias as described by Deeks and col-
leagues [26] were extracted and the methodological
quality of each selected trial was assessed by two
reviewers (LVS and ADS). Special attention was given to
the generation and concealment of the sequence of
randomization, whether an intention-to-treat analysis
was performed or not, and source of funding. These data
were applied in sensitivity analyses to test the stability of
the results.
Review Manager 5 software (RevMan 5; The Nordic
Cochrane Centre, The Cochrane Collaboration, Copen-
hagen, Denmark) was used to perform the meta-analysis.
For time-to-event variables, the effect of the treatment









SWOG 8736 1998 Adequate Unclear Ye
ECOG 1484 2004 Adequate Adequate Ye
GELA LNH 93-1 2005 Adequate Adequate No
GELA LNH 93-4 2007 Adequate Adequate No(HR) of chemotherapy plus RT arm over the chemother-
apy alone arm. The 95% confidence interval (CI) was
calculated for each point estimate. For dichotomous
variables, the effect of treatment was calculated as a risk
ratio (RR), and presented with the correspondent 95%
CI. Data were analyzed using Mantel-Haenszel fixed-
effect method.
Statistical heterogeneity of the results of the trials was
assessed by the chi-square test [27], expressed with the
I2 index, as described by Higgins and colleagues [28].
When heterogeneity was detected, a possible explanation
for it was intensively pursued. If a reasonable cause was
found, a separate analysis was then performed. When
the cause was not apparent and heterogeneity was
caused by divergent data in terms of direction of results,
we chose not to pool the data. Publication bias was eval-
uated by the Egger test [29,30].
Results
Description of studies and quality assessment
Four trials with a total of 1,796 patients met the inclu-
sion criteria (Figure 1) [31-35]. One study was excluded
because RT was employed before chemotherapy in the
combined modality arm [18]. All data were extracted
from the original peer-reviewed publication. There was
no evidence of publication bias (Egger’s test: p = 0.52).
The methodological characteristics of the selected trials
included in this meta-analysis (Table 1) had no impact
on the results obtained, as confirmed by the sensitivity
analysis performed [this data is available upon request].
All trials tested the use of RT after systemic therapy
comprising anthracycline-based chemotherapy (Table 2).
Treatment with cyclophosphamide, doxorubicin, vincris-
tine and prednisone (CHOP) was the preferred regimen
in these trials.
The Southwest Oncology Group (SWOG) 8736 trial
[32] included 401 patients with intermediate- or high-
grade NHL. Stages I and II were allowed, except those
with stage II and bulky disease. Participants were rando-
mized to receive 8 cycles of CHOP or 3 cycles of CHOP
plus involved-field radiation therapy (IFRT) with doses
of 40 to 55 Gy. The trial was designed to address if the
addition of RT may allow the use of less cycles of
chemotherapy. Approximately 20% of the patients had
two or more risk factors (international prognostic indexrial
ithdrawn
escription
α-error β-error ITT Site Sponsor
s No No Yes Multicentric Public
s Yes Yes Yes Multicentric Public
Yes Yes Yes Multicentric Both
Yes Yes Yes Multicentric Both
Table 2 Study population and therapy
Trial Arms N Population Age and PS 0-1 Stage LDH IPI RT
SWOG 8736 CHOP x 8 201 WF groups D-J (DLBCL 75%);
stage I to II non-bulky
> 60y = 49% 0-1 = 96% II 33% " 19% 0-1 = 71% No RT
CHOP x 3 + RT 200 >60y = 50% 0-1 = 97% II 32% " 20% 0-1 = 74% IFRT 40-55 Gy
ECOG 1484 CHOP x 8 112 WF H-J (DLBCL 83%);
stage I bulky to II; complete responders to CHOP only
Median 60y 0-1 = 93% II 70% E 52%, B20% NA NR No RT
CHOP x 8 + RT 103 Median 58y 0-1 = 96% II 68% E 45% B22% NA NR IFRT 30 Gy
GELA LNH 93-1 ACVBP+CT 318 WF H-J or anaplastic according to uKC (DLBCL 81%);
15-60y; aaIPI = 0†; stages I to II
Median 46y 0-1 = 100% II 32% E 46% " 3% 0= 96%† No RT
CHOP x 3 + RT 329 Median 47y 0-1 = 100% II 32% E 52% " 3% 0= 95%† IFRT 40 Gy
GELA LNH 93-4 CHOP x 4 277 WF H-J or anaplastic according to uKC (DLBCL 80%);
>60y; aaIPI = 0†; stages I to II
Median 69y 0-1 = 99% II 32% Bu 8% " 2% 0= 95%† No RT
CHOP x 4 + RT 299 Median 68y 0-1 = 99% II 34% Bu 9% " 3% 0= 95%† IFRT 40 Gy
Abbreviations: ACVBP +CT: doxorubicin 75 mg/m² D1 + cyclophosphamide 1200 mg/m² D1 + vindesine 2 mg/m² D1,5 + bleomycin 10 mg D1,5 and prednisone 60 mg/m² D1-5, 3 cycles with 14 days each and then
consolidative chemotherapy with methotrexate, folinic acid, etoposide, ifosfamide and cytarabine; B: “B” symptoms; Bu: bulky disease; CHOP: cyclophosphamide 750 mg/m² D1+ doxorubicin 50 mg/m² D1 + vincristine
1,4 mg/m² D1 +prednisone 60 mg/m² or 100 mg D1-5, 21 day cycles; DLBCL: diffuse large B cell lymphoma; E: extranodal disease; IFRT: involved-field radiotherapy; IPI: International Prognostic Index; LDH: lactate
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chemotherapy patients, and in 75% of chemotherapy
plus RT patients. With a median follow-up of 4.4 years,
five-year PFS was 64% for CHOP x 8, and 77% for
CHOP x 3 plus RT (p = 0.03). Five-year OS was 72% and
82% (p = 0.02), respectively. In an updated analysis, the
results showed an excess of late relapses and deaths due
to lymphoma in the combined-modality treatment. PFS
and OS curves of the two arms overlapped at 7 and
9 years, respectively [33]. Unfortunately, it was impos-
sible to use these updated results in meta-analysis, due
to lack of extractable data.
The ECOG 1484 trial [34] included patients with a less
favorable prognosis. All patients had at least bulky or
extranodal disease, most of them were in stage II, and
only high-grade NHL was allowed. This study included
352 patients receiving 8 cycles of CHOP. Those who
achieved complete response (61%) were randomized to
receive involved field radiation treatment (IFRT) with
doses of 30 Gy (n = 103) or observation (n = 112). There
were imbalances between groups, with patients allocated
to receive RT presenting more mediastinal involvement
and bulky disease. Six-year DFS was 53% for observation
and 69% for RT (p = .05), and six-year OS rates were
67% and 79% (p = .23), respectively. The trial was
designed to detect a 20% improvement in two-year DFS
using a one-sided significance test. Thus, the sample size
was not adequate to detect a survival advantage of con-
solidative RT.
In the Groupe d'Etudes des Lymphomes de l'Adulte
(GELA) LNH 93–1 trial [31], 647 patients with ALNHL
under 60 years and without age-adjusted IPI risk factors
[36] (ECOG-PS< 2 and normal lactate dehydrogenase
[LDH]) were randomized to receive an intensified induc-
tion chemotherapy (ACVBP) and a consolidative chemo-
therapy regimen or 3 cycles of CHOP plus 40 Gy IFRT.
Bulky disease was present in 11% of patients and extra-
nodal involvement in 50%. Complete response rate was
93% for chemotherapy alone and 92% for combined mo-
dality treatment. Five-year PFS was 82% for ACVBP ver-
sus 74% for CHOP plus RT (p< 0.001). Five-year OS
was 90% and 81%, respectively (p = 0.001).Figure 2 Meta-analysis of overall response rate.The GELA LNH 93–4 trial [35] randomized 576
patients older than 60 with ALNHL and without age-
adjusted IPI risk factors [36] to receive 4 cycles of
CHOP alone or 4 cycles of CHOP plus 40 Gy IFRT.
Bulky disease was present in 9% of patients and extra-
nodal involvement in 48%. Accrual was interrupted
earlier due to increasing evidence that rituximab could
improve efficacy in patients with aggressive NHL
[37,38]. With a median follow-up of 7 years, 5-year PFS
was 61% for CHOP alone and 64% for CHOP plus RT




There were divergences in the definition of response
assessments across, but not within trials. Unconfirmed
complete response was analyzed as complete response in
GELA trials [31,35]. Only complete responders could be
randomized to receive RT or observation in the ECOG
1484 trial [34]. SWOG 8736 [32,33] described only
complete response, so data could not be used for overall
response rate evaluation. Data from 1,198 patients were
available. Response was analyzed according to assessable
patients, as reported in these RCT. Overall response
rates (ORR) were not different between groups (RR 0.98;
95% CI 0.95-1.02; p = 0.33), with no heterogeneity be-
tween trials (p = 0.53; I² = 0%) (Figure 2). Data from
1,483 patients could be pooled for complete response
rate (RR 1.01; 95% CI 0.97-1.04; p = 0.76), with no hetero-
geneity among trials (p= 0.46; I² = 0%) (Figure 3).
Progression-free survival
Four trials comprising 1,796 patients were analyzed for
PFS [31,32,34,35]. Data from the ECOG 1484 trial [34]
could not be obtained for an intention-to-treat analysis
due to insufficient data. Thus, estimation was made
from the published disease-free survival curve from
per-protocol patients. Data from all four trials could
not be pooled due to heterogeneity among them
(p= 0.0001; I² = 86%). The heterogeneity persisted even ex-
cluding trials without intention-to-treat data (p= 0.0002;
Figure 3 Meta-analysis of complete response rate.
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be the main cause of heterogeneity, maybe due to consid-
erable differences in intensity and duration of systemic
therapy in both arms. Excluding the GELA LNH 93–1
trial [31], PFS was longer for combined-modality
treatment (HR 0.81; 95% CI 0.67-0.98; p = 0.03), with
an acceptable heterogeneity among trials (p= 0.03;
I² = 35%) (Figure 4).
Pooling data from trials whose arms had the same
chemotherapy regimen (791 patients) [34,35] showed
that the addition of RT to systemic therapy resulted in
no improvement in PFS (HR 0.86; 95% CI 0.69-1.06;
p = 0.16). In this analysis, it was not possible to exclude
heterogeneity among trials (p = 0.17; I² = 46%).
Overall survival
Again, data from ECOG 1484 trial [34] could not be
obtained for an intention-to-treat analysis due to lack of
an adequate description of results. Thus, estimation was
made from the published overall survival (OS) curve
from “as treated” patients. Although all trials
[31,32,34,35] reported data of survival analysis compris-
ing 1,796 patients, results from four trials could not be
pooled due to heterogeneity among them (p = 0.0009;
I² = 82%). Even excluding the ECOG 1484 trial, there
was still heterogeneity detected among trials (p = 0.0009;
I² = 86%). The GELA LNH 93–1 trial [31] seemed to be
mainly responsible for the heterogeneity, again, possibly
due to considerable differences in intensity and duration
between systemic therapy in both arms. However, evenFigure 4 Meta-analysis of progression-free survival after exclusion ofexcluding the GELA LNH 93–1 trial [31], we could still
detect heterogeneity among trials (p = 0.04; I² = 68%).
Pooling data only from the studies whose arms had
the same chemotherapy regimen [34,35], the addition of
RT showed no improvement in OS (HR 1.00; 95% CI
0.79-1.26; p = 0.99). Even in this analysis, there was con-
siderable heterogeneity among trials (p = 0.15; I² = 51%).
Toxicity
In the SWOG 8736 trial [32] there were no differences
in life-threatening toxicity or death between chemother-
apy alone and chemotherapy plus RT arms (30% and
40%; p = 0.06; one death in each arm). Patients assigned
to chemotherapy alone arm had more congestive heart
failure than patients assigned to chemotherapy plus RT
arm. More patients in the chemotherapy alone arm did
not complete the assigned regimen (28 and 3 patients,
respectively, p< 0.01).
In the ECOG 1484 trial [34], toxicity was described
according to the phase of therapy (chemotherapy and
then RT or observation). There was only one grade 4 ad-
verse event (thrombocytopenia) in the RT arm and none
in the observation arm. GELA LNH 93-1 [31] and 93-4
[35] did not describe toxicity individually for each arm,
but life-threatening toxicity appeared to occur in a small
number of patients.
Due to differences in reporting adverse events, it was not
feasible to pool toxicity data. Radiation therapy appeared
to be well tolerated, with side effects dependent mainly on
the location of disease.GELA LNH 93-1.
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There was no evidence of publication bias (Egger’s test:
p = 0.52). The methodological characteristics of the
selected trials included in this meta-analysis (described
in Table 1) had no impact on the results obtained, as
confirmed by the sensitivity analysis performed [this data
is available upon request].
Discussion
Early stage aggressive NHL is a heterogeneous group of
diseases with a high potential of cure. Systemic therapy
has been the mainstream of therapy for more than
20 years. Additionally, RT had shown to increase re-
gional control, which may lead to improvement in sur-
vival. Other possible secondary benefits of radiotherapy
could be the diminishing of chemotherapy late effects.
Considering that relapses usually occur at the site of
disease, and RT alone can cure up to 70% of patients, it
seems rational to test RT after chemotherapy in patients
with ALNHL. The achievement of local control could
be, in this setting, a surrogate of survival improvement.
Since the publication of the SWOG 8736 trial [32], ra-
diation therapy has become the standard therapy in
North America. Unfortunately, the benefit of the treat-
ment in prolonging PFS and OS has not been sustained
over the years [33]. The ECOG 1484 trial [34] evaluated
the addition of RT in patients with complete response
with unfavorable results. In the trial, DFS (but not OS)
was better in the combination arm. The GELA LNH
93–1 trial [31] compared short-course chemotherapy
regimen plus RT to an intensified chemotherapy regi-
men. The group receiving the ACVBP regimen showed
improved survival when compared to the group receiv-
ing CHOP for 8 cycles [39] for non-localized NHL or
CHOP plus RT for localized disease [31]. Despite that,
the more intensive regimen has not been widely
accepted due to long term adverse events, like acute
myelogenous leukemia, myelodysplastic syndrome and
lung cancer [40]. This is especially important for patients
with one IPI risk factor [36], in whom cure rates usually
exceed 80% with CHOP-based chemotherapy [31,32].
Thus, some advocate ACVBP should not be considered
a valid alternative to CHOP in patients without high
risk of recurrence. Recently, ACVBP plus rituximab
(R-ACVBP) was compared to CHOP plus rituximab in
young patients with advanced diffuse large B-cell lymph-
oma. With a median follow up of 44 months, R-ACVBP
improved overall survival [41]. Long term follow up is
needed to address long term adverse events.
Both the GELA LNH 93-1 [31] and SWOG 8736
[32,33] trials suggested that radiotherapy cannot replace
inadequate chemotherapy regimens. The GELA LNH
93–4 trial [35] evaluated the addition of RT to 4 cycles
of CHOP in the treatment of elderly patients withALNHL. No improvements in terms of PFS or OS were
observed. Five-year PFS in the chemotherapy alone arm
was 61%, comparable to 64% in the chemotherapy alone
arm after 8 cycles of CHOP in the SWOG trial in
younger patients with a more favorable prognosis [32].
This systematic review showed that RT could enhance
PFS after chemotherapy, with no impact on ORR and
OS. Heterogeneity among trials limits a definite conclu-
sion. The interventions under study and trial design
characteristics, such as definition of outcomes, inclusion
criteria, risk factors and statistical considerations can
cause substantial differences when pooling data, and
may constitute the major causes of heterogeneity found
in the current meta-analysis. Our results are consistent
with those addressed in an overview published in 2003
[7]. The high efficacy of chemotherapy in inducing re-
mission of ALNHL would increase the number of sub-
jects in clinical trials evaluating the role of consolidative
RT. Thus, all included trials were individually underpow-
ered to assess improvement of response rate, PFS and
OS.
More recently, rituximab has been incorporated into
the treatment of patients with NHL, with clear benefits
in PFS and OS [37,38]. Now the combination of rituxi-
mab with a CHOP-based chemotherapy regimen has
been considered as the standard treatment for aggressive
NHL patients. There is still no prospective trial evaluat-
ing the role of RT in the era of targeted therapy, so far
the role of radiation after chemotherapy plus rituximab
remains speculative. Recently, a retrospective study sug-
gested improvement in both OS and PFS with consolida-
tive RT after rituximab-CHOP chemotherapy. This
improvement occurred in both early (I and II) and
advanced stage (III and IV) [42]. Despite these gains,
these evidences are not sufficient to support or repel the
use of consolidative RT in ALNHL. The possible inter-
action between rutuximab and radiation therapy makes
the results of these combinations unpredictable. Thus,
radiation therapy should be studied in this new context,
and cannot be considered a standard of care until its
benefit is proven. Some studies have recently addressed
the role of radiation therapy in the management of loca-
lized disease in patients with positive Positron Emission
Tomography (PET) after chemotherapy [43-45]. Radi-
ation therapy yielded interesting survival results in this
subset of patients, providing a rational selection tool for
consolidative radiotherapy.
There are still many unanswered questions regarding
the management of early stage aggressive NHL. The
ideal chemotherapy regimen, its optimal duration, the
duration of rituximab treatment, the benefits of adding
RT and its dose are important issues that need further
evaluation by high-quality RCT. Our systematic review
suggests that RT prolongs PFS and can be considered an
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prolonged schedule of chemotherapy. Further evaluation
of RT after chemotherapy is still needed.
Conclusions
In conclusion, RT prolongs PFS, with no impact on OS.
It must be considered an option for patients who cannot
tolerate a high dose or prolonged schedule of chemo-
therapy. Further investigation of the role of RT in the
era of targeted therapy is needed.
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